Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 9.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 672,407 shares of the company's stock after selling 66,937 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Haleon were worth $6,919,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC purchased a new stake in Haleon during the first quarter worth about $29,000. FIL Ltd increased its position in shares of Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after acquiring an additional 1,270 shares in the last quarter. Continuum Advisory LLC increased its position in shares of Haleon by 152.4% in the first quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock worth $49,000 after acquiring an additional 2,870 shares in the last quarter. Addison Advisors LLC increased its position in shares of Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares in the last quarter. Finally, Lindbrook Capital LLC increased its position in shares of Haleon by 22.6% in the fourth quarter. Lindbrook Capital LLC now owns 9,355 shares of the company's stock worth $89,000 after acquiring an additional 1,724 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Stock Down 0.8%

NYSE HLN traded down $0.08 during trading hours on Thursday, reaching $10.42. 12,691,179 shares of the company traded hands, compared to its average volume of 9,244,103. Haleon PLC Sponsored ADR has a 12 month low of $8.25 and a 12 month high of $11.42. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $46.86 billion, a PE ratio of 26.72, a PEG ratio of 2.99 and a beta of 0.31. The company has a 50 day moving average of $10.71 and a two-hundred day moving average of $10.12.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, May 27th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Barclays restated an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a research note on Friday, May 9th. Finally, BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price for the company in a research note on Tuesday, May 27th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $12.33.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.